Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • Patients who cannot receive tenofovir disoproxil fumarate or tenofovir alafenamide because of current or high risk of renal dysfunction should be treated with a fully suppressive antiretroviral regimen that does not include either drug, and renally dosed entecavir should be added to the regimen (Management Guidelines)[DHHS OI]
    • For patients with HIV and HBV coinfection and renal dysfunction but with creatinine clearance of 30 mL/min to 59 mL/min, an ART regimen containing tenofovir alafenamide and emtricitabine is preferred
    • For patients with HIV and HBV coinfection and creatinine clearance < 30 mL/min, adding renally dosed entecavir to a suppressive non-tenofovir–containing ART regimen is preferred

Action required